---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-009939"
form_type: "8-K"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2023-02-02T23:59:59+00:00"
generated_at: "2026-06-20T02:13:00.675168+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Sesen Bio discloses ~$0.34/shr special dividend, 25.2% stake in combined company in Carisma merger

## Summary
- Expected one-time cash dividend of ~$70M ($0.34/shr) upon merger close; plus CVR up to $0.14/shr from legacy asset sales and Roche milestone.
- Sesen Bio stockholders to own 25.2% of combined company valued at $357M, led by Carisma management.
- Board conducted 4-month strategic review, contacted 100+ parties, received 42 bids; determined merger maximizes value vs dissolution.
- In dissolution scenario, estimated initial distribution only $0.40-$0.60/shr, available after 6+ months, full process up to 3 years.
- Special stockholder meeting on March 2, 2023; Sesen Bio urges vote 'FOR'.

## SEC filing metadata
- accession: 0001104659-23-009939
- form_type: 8-K
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2023-02-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000110465923009939/0001104659-23-009939-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000110465923009939/tm235275d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-009939
- JSON: https://secwatch.observer/filing/0001104659-23-009939.json
- Plain text: https://secwatch.observer/filing/0001104659-23-009939.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.